How to value a life sciences patent before you start a company
Most researchers who ask "what is my patent worth?" are asking the wrong question. Here is how the calculation actually works.
Most researchers who ask "what is my patent worth?" are asking the wrong question. Not because the question is unimportant. It is critically important. But the frame is wrong.
A patent, in isolation, is worth very little. What has value is the commercial potential of the product that could be built from it.
What has value is the commercial potential of the product that could be built from the patent, adjusted for the probability that it will get there, discounted for the time it will take, and benchmarked against what comparable assets have actually traded for in the market.
That calculation is not a legal exercise. It is not a matter of how well-drafted the claims are or how broad the protection is. It is a financial exercise, and it requires inputs that most researchers have never been asked to produce before.
This article explains how that calculation works, what inputs it requires, why most early attempts produce numbers that are either wildly optimistic or uselessly vague, and what a researcher can actually do to arrive at a defensible estimate before committing to the spinout journey.
Why patent valuation in life sciences is different
In most industries, IP is valued by reference to the royalty income it generates. A software patent, a brand, a trade secret: these can be valued by estimating the revenues they protect and applying a royalty rate.
Life sciences patents rarely generate royalties in their early stages. They protect inventions that are years away from commercial use, if they get there at all. The clinical and regulatory journey between a filed patent and a commercial product is long, expensive, and non-linear. Most assets do not complete it.
Clinical phase transition probabilities
Phase I
65%
advance
Phase II
30%
advance
Phase III
58%
approved
Overall
~11%
reach market
Source: ScienceDirect (2025), CatalystAlert analysis of 2,092 compounds across 19,927 clinical trials
These probabilities are the foundation of life sciences valuation. They are not peripheral adjustments to a base case. They are the central fact around which every other input is organised.
The three methods - and when each applies
There are three established approaches to valuing a life sciences patent. Each has its place. None of them works well in isolation.
Income approach
rNPV
Risk-adjusted net present value. The industry standard for early-stage life sciences assets.
Best for: assets with modelable revenue potential and known phase probabilities
Market approach
Comparable transactions
Benchmarking against deals involving assets at a similar stage, indication, and modality.
Best for: validating rNPV against what the market actually pays
Cost approach
Reproduction cost
What would it cost to replicate the data, experiments, and patent from scratch?
Best for: establishing a valuation floor when rNPV is uncertain
How rNPV works
rNPV = Σ [ (Revenuet × Pcumulative − Costt × Pt) / (1 + r)t ]
Revenuet
Projected cash flow in year t
Pcumulative
Cumulative probability of reaching year t
Costt
Development costs in year t
r
Discount rate (cost of capital)
Discount rates by stage and investor type
Early-stage biotech
40.1%
Average discount rate
Mid-stage biotech
26.7%
Average discount rate
Pharma (internal R&D)
10–13%
Cost of capital
Source: Alacrita survey of 242 biotech professionals with valuation experience
The gap between these rates is not a matter of precision. It is a reflection of who is doing the calculation and what return they require.
The licensing deal benchmark
Licensee's rNPV
€100M
Standard range
25–35%
Total deal value to licensor
€25–35M
Source: Vision Lifesciences - includes upfront, milestones, and royalty NPV
Like what you're reading?
Subscribe for more strategic notes on biotech and venture design.
The inputs that determine everything
The rNPV calculation is only as credible as the assumptions that go into it. Three inputs drive most of the value, and each is harder to estimate honestly than it appears.
1. Peak sales potential
The single largest driver of rNPV. A difference of a factor of two in peak sales produces a proportional difference in valuation.
Top-down (wrong)
"The global oncology market is $200B. We only need 0.1% = $200M in peak sales."
Bottom-up (right)
"12,000 eligible patients × €45K/year × 35% market share at year 5 = €189M peak sales."
2. Probability of success
Must be calibrated to the specific asset, not taken from published averages. An asset in oncology faces different probabilities than one in rare disease. A small molecule faces different probabilities than a cell therapy.
Run as scenario analysis, not a single point estimate:
- What is the value if Phase II data is positive?
- What is the value if the data is borderline?
- What is the value in a licensing vs. acquisition scenario?
3. Development costs
Consistently underestimated. Researchers from academic settings frequently underestimate the cost of GMP manufacturing, clinical trial management, regulatory submission, and institutional overheads.
Reality check: The Tufts Center estimates the cost to bring a new molecular entity through clinical development runs into hundreds of millions of euros. Even a diagnostic through to CE-IVD or FDA clearance typically costs tens of millions.
What a pre-company patent is actually worth
At the pre-company stage, the asset typically has filed patent claims, some preclinical data, and perhaps early proof-of-concept results. It does not have a defined development plan, a management team, a regulatory strategy, or a manufacturing process.
For most early-stage life sciences assets, the rNPV falls in the range of a few million to low tens of millions of euros.
This sounds low to researchers who have spent a decade on the science. It is consistent with what the market actually pays. Venture investors targeting a 10–30× return on a seed investment of €2–3M are implying a post-money valuation in that range. The arithmetic is not negotiable.
The purpose of the valuation exercise is not to arrive at the highest defensible number. It is to arrive at the most credible one.
The non-obvious inputs that most models ignore
Remaining patent life
Cash flows only occur within the patent-protected commercial window. An asset with 10 years of remaining protection at launch generates significantly less value than one with 15.
SPCs in Europe and patent term extensions in the US can add up to 5 years - worth quantifying explicitly.
Freedom to operate
The patent protects what you invented. It does not guarantee the right to commercialise it. FTO analysis is separate and can significantly reduce net economic return.
Experienced investors conduct FTO analysis during due diligence. Founders should conduct it before the valuation.
What the valuation is really for
The exercise of valuing a patent before starting a company is not primarily about arriving at a number to put in a term sheet. It is about stress-testing the assumptions underlying the commercial strategy.
- Peak sales forces a realistic analysis of competitive landscape and reimbursement
- Probability of success forces honest assessment of preclinical data and regulatory pathway
- Development costs forces realistic understanding of what it takes to reach the first inflection point
The valuation exercise is a diagnostic tool as much as a financial one. The number it produces is less important than the understanding it generates.
A researcher who has worked through the rNPV model carefully is a researcher who is ready to have a substantive conversation with an investor.
Not because the number will be agreed without negotiation, but because the conversation will be about the assumptions, not about whether the homework has been done.
That conversation is where the deal begins.
A patent is just the starting line. Let's translate your intellectual property into a commercial architecture and unlock its true market valuation.
Assess your asset's value